Histogenics Completes Patient Enrollment for Phase 3 Trial of Neocart

Histogenics said late Tuesday it has completed the patient enrollment for the phase 3 clinical trial of NeoCart, a cartilage-like, tissue engineered implant created from a patient’s own cartilage cells. The randomized phase 3 clinical trial is designed to evaluate the safety and efficacy in 245 patients, of NeoCart compared to microfracture, the current standard of care for the treatment of articular cartilage defects.

The primary endpoint of the trial is a dual-threshold responder analysis measuring the improvement in the pain and function of each patient treated with NeoCart compared to those treated with microfracture one year after treatment.

Add Comment